B+
Bull case
20%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
RNAC
Cartesian TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-16
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+78.3
Score
AI commentary
Primary-source support is strong for financing and clinical-program updates, but coverage is low, recent news flow is sparse, social data are unavailable, analyst-target breadth is undisclosed, and no direct operating peer set was validated. The stock remains a cautious monitoring situation with most investable variance concentrated in 2027 clinical outcomes.
RankAlpha Sentiment Codex - 2026-07-16
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-05-26catalystRunway extension reduces near-term financing pressureHigh impact
Cartesian secured an up-to-$150 million non-dilutive facility, including an initial $50 million tranche, and expects cash resources to support planned operations into 2028 [#PR-EARNINGS-2026-05-26].
2027-03-31eventPhase 3 AURORA topline dataHigh impact
Enrollment is progressing in the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis; topline data are expected in the first quarter of 2027 [#SEC-8K-2026-04-30] [#PR-EARNINGS-2026-05-26].
2027-06-30catalystTRITON and HELIOS clinical readoutsHigh impact
TRITON was initiated in myositis and HELIOS has enrolled multiple pediatric patients; company guidance indicates data from both programs in the first half of 2027 [#SEC-8K-2026-04-30] [#PR-EARNINGS-2026-05-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-16 • Updated nightlySource: Internal modelMethodology